Prostate Triple (P63/KRT/P504S), Technical Component Only
Use
The prostate triple assay consists of 3 antibodies: P63, HMW KRT (34betaE12), and P504S. This multiplex is used in the diagnosis of high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancer. P63 (nuclear) and HMW KRT (cytoplasmic) are expressed in normal myoepithelial cells that surround the prostatic epithelial cells. This myoepithelial layer is lost in carcinoma. The test aids in the identification of high-grade prostatic intraepithelial neoplasia and prostate cancer.
Special Instructions
Not provided.
Limitations
This test does not include pathologist interpretation, only technical performance of the stain. Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks. The charge of glass slides can be affected by environmental factors and subsequently may alter slide staining. Sending unsuitable glass slides can result in inconsistent staining due to poor slide surface chemistry.
FDA ApprovedNew York Approved
Methodology
Immunoassay (IHC)
Biomarkers
HMW KRT (34betaE12)
ProteinP504S
ProteinP63
Protein
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Immunostain Technical Only Envelope
Causes for Rejection
Wet/frozen tissue; Cytology smears; Nonformalin fixed tissue; Nonparaffin embedded tissue; Noncharged slides; ProbeOn slides; Snowcoat slides